Clinical trial programme with new c-Met inhibitor for kidney cancer initiated in Australia and New Zealand

CBT Pharmaceuticals (a US and China-based biopharmaceutical company) announced the launch of its APOLLO Oncology Clinical Trials Programme this week. The APOLLO series of trials will investigate whether the c-Met inhibitor, bozitinib (CBT-101) can work in combination with immunotherapies to improve response rates and patient outcomes. The first study in the APOLLO programme has been […]

read more

Neutrophil-lymphocyte ratio may predict survival following surgery for kidney cancer

A recent study published in European Urology Focus reports that the neutrophil-lymphocyte ratio (NLR) in the blood before surgery may be used as a biomarker to predict survival following cytoreductive nephrectomy plus removal of the tumour blood clot (thrombectomy) for renal cell carcinoma (RCC). The study involved 332 patients with metastatic RCC and tumour thrombus. Those […]

read more

Managing immune-related adverse events

Immune-related adverse events (irAEs) are side effects that can develop when being treated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. These side effects develop because the immune system has been activated by an immunotherapy drug, resulting in a highly active immune response. This immune response can damage healthy tissue or cause autoimmune […]

read more

Avelumab plus axitinib combination shows promise

A clinical trial looking at the combination of avelumab plus axitinib for renal cell carcinoma (RCC), JAVELIN Renal 101, has released some positive top-line results, which will be presented at an upcoming medical congress. JAVELIN Renal 101 is a pivotal phase III study with 886 renal cancer patients. As part of a planned interim analysis, […]

read more

Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA

The European Association of Urology (EAU) Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition (IKCC) have issued a joint statement about the rejection of ipilimumab and nivolumab for kidney cancer by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The EAU are saying that the CHMP’s decision […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more
Showing 1 to 6 of 436 results